[Experimental multihormone therapy on human breast carcinomas grown in nude mice]

T Fukutomi1

  • 1Department of Surgery, School of Medicine, Keio University.

Nihon Geka Gakkai Zasshi
|December 1, 1989
PubMed

Insights

Combination hormone therapy using tamoxifen (TAM) and aminoglutethimide (AMG) shows promise for breast cancer treatment. This combined approach demonstrated superior efficacy in preclinical models compared to individual agents.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Context:

  • Investigated experimental multihormone therapy for hormone-dependent breast cancer.
  • Utilized human breast carcinoma xenografts in nude mouse models.

Purpose:

  • To evaluate the efficacy of tamoxifen (TAM), aminoglutethimide (AMG), and medroxyprogesterone acetate (MPA) as single agents and in combination for hormone-dependent breast cancer.
  • To explore the mechanisms underlying the antitumor effects of these hormonal agents.

Summary:

  • Tamoxifen (TAM) exhibited 100% efficacy, while medroxyprogesterone acetate (MPA) showed only 17% efficacy.
  • Combination therapy with TAM and aminoglutethimide (AMG) was more effective than either agent alone.
  • Aminoglutethimide (AMG) reduced estrogen levels, potentially enhancing TAM's anti-estrogen receptor activity.

Impact:

  • Combination hormone therapy, especially TAM and AMG, presents a promising strategy for clinical breast cancer treatment.
  • Understanding hormonal interactions provides insights into optimizing breast cancer therapeutic regimens.

Related Concept Videos